Effects of age and estrogen status on the skeletal IGF regulatory system. Studies with human marrow

Endocrine
C J RosenJulie Glowacki

Abstract

Human marrow was obtained as material discarded during total hip replacement and was established in culture with phenol red-free alpha-MEM with 10% fetal bovine serum (FBS) and antibiotics. Insulin-like growth factor I (IGF-I) and its binding proteins were secreted by human marrow cells, in amounts that increased with time in culture. Western ligand blotting showed that insulin-like growth factor binding protein-3 (IGFBP-3) accounted for the majority (approximately 75%) of the secreted binding proteins. Evidence for marrow secretion of BP-3 protease was found by electrophoretic analysis of mixtures of radiolabeled IGFBP-3 and marrow-conditioned media. The amount of constitutive secretion of IGFBP-3 increased with age of the subject (r = 0.97, p = 0.0058). A notable exception was marrow from a postmenopausal women on estrogen replacement therapy (ERT) at the time of surgery; her marrow secreted 89.3 ng/mL after 14 d in vitro, only 38% of the IGFBP-3 that was secreted by cultures from two age-matched peers (208.8 and 285.2 ng/mL). This in vivo effect of estrogen was matched by an in vitro experiment in which 10(-8) M 17-beta estradiol suppressed IGFBP-3 to 60% of the constitutive level. In all cultures of marrow from postmenopaus...Continue Reading

References

Aug 1, 1991·Endocrinology·J M SuttieP D Gluckman
Aug 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·S Gartner, H S Kaplan
Nov 1, 1995·The Journal of Clinical Endocrinology and Metabolism·H BismarJ Pfeilschifter
Feb 1, 1995·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·M E Cohen-SolalM C De Vernejoul
Feb 1, 1995·Endocrine Reviews·J I Jones, D R Clemmons
Jun 1, 1994·Proceedings of the Society for Experimental Biology and Medicine·C J RosenS J Hunter

❮ Previous
Next ❯

Citations

Jun 26, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HadjiJ Green
Dec 8, 2009·Endocrinology·Shuanhu ZhouJulie Glowacki
Oct 9, 2007·Archives of Physiology and Biochemistry·A HoeflichD Kiepe
Mar 12, 2009·Ageing Research Reviews·Shirin Hooshmand, Bahram H Arjmandi
Mar 5, 2005·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Takehiro MatsubaraYukio Kato
Jun 24, 2004·Journal of Cellular Biochemistry·Massimiliano MonticonePatrizio Castagnola
Jun 17, 1998·The Journal of Clinical Endocrinology and Metabolism·D CheleuitteJ Glowacki
Nov 1, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P HadjiJ Green

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Nature Clinical Practice. Rheumatology
Luigi Gennari, Giuseppe Martini
Growth Hormone & IGF Research : Official Journal of the Growth Hormone Research Society and the International IGF Research Society
M Fernández-CancioM L Granada
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
J P ChuteK M Shakir
Thyroid : Official Journal of the American Thyroid Association
Jan BuceriusHans-Jürgen Biersack
© 2021 Meta ULC. All rights reserved